420 related articles for article (PubMed ID: 11418315)
21. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR
Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187
[TBL] [Abstract][Full Text] [Related]
22. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A
J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764
[TBL] [Abstract][Full Text] [Related]
23. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
[TBL] [Abstract][Full Text] [Related]
24. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
[TBL] [Abstract][Full Text] [Related]
26. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
Rizvi SN; Visser OJ; Vosjan MJ; van Lingen A; Hoekstra OS; Zijlstra JM; Huijgens PC; van Dongen GA; Lubberink M
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):512-20. PubMed ID: 22218876
[TBL] [Abstract][Full Text] [Related]
27. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
28. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
29. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
[TBL] [Abstract][Full Text] [Related]
30. Biodistribution and Dosimetry of Indigenously Produced
Adnan A; Deep K; Kameswaran M; Nikam D; Shanmukaih C; Dash A; Banerjee S; Basu S
J Nucl Med Technol; 2019 Dec; 47(4):292-299. PubMed ID: 30413603
[TBL] [Abstract][Full Text] [Related]
31. The role of nuclear medicine in the treatment of non-Hodgkin's lymphoma (NHL).
Bischof Delaloye A
Leuk Lymphoma; 2003; 44 Suppl 4():S29-36. PubMed ID: 15154740
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
33. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Zimmer AM
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
[TBL] [Abstract][Full Text] [Related]
34. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
[TBL] [Abstract][Full Text] [Related]
35. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
[TBL] [Abstract][Full Text] [Related]
36. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Gordon LI
Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
[TBL] [Abstract][Full Text] [Related]
37. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
[TBL] [Abstract][Full Text] [Related]
39. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
Gregory SA
Semin Oncol; 2003 Dec; 30(6 Suppl 17):17-22. PubMed ID: 14710399
[TBL] [Abstract][Full Text] [Related]
40. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
Dahle J; Bruland OS; Larsen RH
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):186-92. PubMed ID: 18722269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
